Drug intelligence / Profile preview

NVA1501-16

Development stage: Preclinical
Lead developer: Novassay
Modality: Small Molecules

Overview

NVA1501-16 is a preclinical-stage small molecule developed by Novassay that targets the alpha-2/delta-1 (α2δ-1) subunit of voltage-gated calcium channels. This subunit is a well-established target for the treatment of neuropathic pain, as it modulates the trafficking and function of calcium channels involved in pain signaling. NVA1501-16 is being investigated for its potential in treating neuropathic pain and solid tumors, where α2δ-1 may play a role in cancer cell proliferation or tumor-associated pain management.

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on NVA1501-16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVA1501-16.

Explore the full profile